Introduction
The t(9;22)(q34;q11) chromosomal translocation has been identified as the causative genetic aberration in chronic myelogenous leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph þ -ALL), and results in a constitutively activated BCR/ABL tyrosine kinase. [1] [2] [3] [4] Imatinib mesylate (IM) is clinically very effective in the treatment of leukemias harboring the BCR/ABL fusion protein. 5, 6 However, despite encouraging response rates, 5, [7] [8] [9] BCR/ABLkinase point mutations may develop in advanced phase CML and Ph þ -ALL under prolonged IM exposure and cause clinical resistance to IM. [10] [11] [12] [13] [14] [15] Reactivation of the BCR/ABL kinase activity in the presence of IM through point mutations located within the BCR/ABL kinase domain remain clinically the most relevant mechanism for secondary resistance to IM. 11, 12, 14 It is unclear how IM-naïve cells sustain survival before clinically overt BCR/ABL-dependent resistance occurs. However, recently, it has been shown that compensatory activation of the Ras/MAPK-signaling may contribute to survival of BCR/ABLpositive cells under IM selection pressure. [16] [17] [18] [19] The antiapoptotic phosphatidylinositol 3-kinase (PI3K)-Akt signaling is involved not only in BCR/ABL-mediated transformation, 20, 21 but also in resistance against other kinase inhibitors such as gefintinib, 22 and blocking PI3K was synergistic with IM treatment in antagonizing BCR/ABL. 23 The serine-threonine kinase mammalian target of rapamycin (mTor) is downstream of PI3K-Akt and regulates cell growth and proliferation. 24 mTor phosphorylates p70S6-kinase (p70S6K) and eukaryotic initiation factor 4E-binding protein-1 (4E-BP1), both of which regulate mRNA translation. The p70S6-kinase is regulated by mTor and PI3K/PDK-1 pathways [25] [26] [27] [28] and was originally identified as a kinase that regulates serine phosphorylation of the 40S ribosomal S6 protein (rpS6). This kinase plays important roles in various cellular functions, such as regulation of cell-cycle progression, cell survival, and initiation of mRNA translation via phosphorylation of rpS6. 29, 30 The macrolide rapamycin (Rap) binds to the immunophilin FKBP12, 25 and this complex specifically inhibits mTor, causing clinically relevant immunosuppression 24, 31 but also anti-tumor effects. 32, 33 PI3K-inhibitors and Rap synergize with IM in causing apoptosis of BCR/ABL-positive cell lines in vitro and overcoming manifest IM resistance mediated by BCR/ABLkinase point mutations in vitro and in a mouse model. 34, 35 Here, we show that the PI3K/Akt/mTor-signaling becomes activated in IM-naïve cells in response to IM challenge and facilitates incipient IM resistance. In contrast, during clinically overt IM resistance through BCR/ABL-kinase mutations, an autonomous activation of the downstream targets of BCR/ABL, Akt and mTor, was found in selected patients, and may be associated with responsiveness to mTor inhibitor treatment.
Materials and methods

Inhibitors
IM was kindly provided by Novartis Pharma (Basel, Switzerland). Stock dilutions were prepared in dimethylsulfoxide (DMSO) and stored as a 10 mM solution at À201C.
Rap was purchased from (Sigma, St Louis, MO, USA). Stock dilutions were prepared in ethanol and stored as 2 mM solution at À201C. Everolimus (RAD001) 36 was kindly provided by Novartis. Stock was prepared in DMSO and kept as a 20 mM solution at À201C. Wortmannin (Calbiochem, Bad Soden, Germany) was prepared as a 20 mM stock and kept at À201C; SH-6 (Alexis Corp., Lausen, Switzerland) was solubilized in water and stored as a 10 mM stock solution at 41C.
Patient blood samples
In all, 10-20 ml peripheral blood or bone marrow samples were obtained after written informed consent. The collection of blood samples was approved by the local ethics committees.
Cell culture, clonal in vitro resistance induction BCR/ABL-positive LAMA-84 cells (LAMA) were obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ, Braunschweig, Germany) and maintained in RPMI1640 medium supplemented with 1% glutamine, 10% fetal calf serum (FCS) (all Gibco/BRL, Eggenstein, Germany), and 1% penicillin/streptomycin (Biochrom KG, Berlin, Germany). Single cell clones were generated from LAMA cells by limited dilution cloning using cloning plates (Greiner Bio-one GmbH, Solingen, Germany). Each clone was expanded to individual cultures. Aliquots of the thus obtained d0 populations (d0) were cryo-preserved and each clone was exposed both to raising concentrations of IM ( þ IM) or mocktreatment (ÀIM, control culture). IM-exposure was started with 0.05 mM and increased every 10 days by 0.05 mM only in case of greater than 70% viability in culture, as assessed by the Trypan blue exclusion method. The IM-concentration remained unchanged if the viability was between 30 and 70%, and IM was withdrawn in case of o30% viability, which was referred to as rescue. Rescue periods depended on recovery times. IM was readded to 50% of the last achieved IM level in case of 490% viability in the culture. Cell aliquots, lysates and RNA of control-and IMexposed cultures of each clone were cryo-preserved in regular time intervals after d0 (summarized in Supplementary Figure 1) . In other experiments, IM resistance was generated accordingly, but in the steady presence of 5 nM Rap, which was renewed every 3 days.
Primary cells were cultured in RPMI1640 plus 20% FCS supplemented with 20 ng/ml stem cell factor, 10 ng/ml interleukin-6, 20 ng/ml granulocyte colony stimulating factor and interleukin-3 (all from PeproTech, London, UK).
RT-PCR sequencing of the BCR/ABL kinase domain BCR/ABL tyrosine kinase domain (gene accession number: U07563) was sequenced after reverse transcriptase (RT)-PCR amplication from cDNA, as previously described. 14, 15 Apoptosis measurement Apoptosis was measured as previously described 37 using, the AnnexinV-FITC apoptosis detection kit (Calbiochem, Schwalmbach, Germany) according to the manufacturer's recommendations.
Proliferation
Cell proliferation was measured using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromid (MTT) colorimetric reduction method as described by the manufacturer (Sigma Chemical 
Western blot analysis
Western blotting of LAMA clones or primary cells was performed essentially as described previously 37 using the following purchased antibodies: anti-c-ABL antibody (sc-23) (Santa Cruz Biotechnology, Inc., Heidelberg, Germany), antiAkt and anti-pAkt (Ser473) (both from Cell Signaling Technologies, Berverly, MA), anti-p T389 p70S6K (Ser389) (Cell Signaling Technologies, Beverly, MA, USA), and anti-Actin (AC-74) (Sigma, Munich, Germany).
Akt1-siRNA transfection 1 Â 10 6 cells (clone 10 þ IM) were transiently transfected with 2.5 mg of anti-human Akt-1-specific siRNA (high performance validated siRNA) purchased from Qiagen (Hilden, Germany) and, alternatively, 2.5 mg of control si-RNA (Qiagen). Transfection was performed using the Amaxa Nucleofector Device (program T-16) with a cell-line specific Nucleofector kit V (Amaxa GmbH, Cologne, Germany) according to the manufacturer's recommendations. Using this program, the transfection efficiency of LAMA cells 24 h post-transfection using an eGFPplasmid (Amaxa) was greater than 80%. Western blotting and apoptosis was assessed 48 h after transfection.
Cell cycle analysis
Flow cytometric analysis of the cell cycle was performed by adding cold ethanol (À201C) to the cells for the naked nuclei preparation. Then, 1 Â 10 6 cells were centrifuged, washed with PBS, and suspended in fluorescence-activated cell sorter (FACS) buffer containing 3.4 mM sodium citrate, 10 mM NaCl, 0.1% NP40, and 50 mg/ml propidium iodide for 1 h at 41C The data were analyzed by the CellQuest and ModFit software (Becton Dickinson, San Jose, CA, USA).
Akt kinase assay
The Akt activity assay was performed using the Akt Kinase Assay Kit (Cell Signaling, Beverly, MA, USA). Whole-cell extracts from 3 Â 10 6 LAMA cells were immunoprecipitated with immobilized anti-Akt antibody, and in vitro kinase assays were performed using GSK (glycogen synthase kinase-3)-fusion protein as a substrate according to the manufacturer's instructions. Phosphorylation of GSK-3 was detected with anti-(phospho-GSK-3).
Mutagenesis screen
This assay was performed as recently described. 38 Briefly, Ba/F3 Mig EGFPp185 wild-type cells were cultured in 96-well plates in a density of 4 Â 10 5 cells per well in the presence of IM at 2 mM without everolimus, or in the presence of IM at 2 mM and everolimus at 0.1 or 0.5 nM. The concentration of IM was increased to 3 mM after 72 h and to 4 mM after 96 h. Single colonies growing out on the bottom of the well were counted.
Results
IM-induced Akt/mTor activation mediates survival before emergence of strong IM-resistance in vitro
To generate IM-resistant cell clones, IM-naïve individual LAMAclones were exposed to increasing concentrations of IM ( þ IM) or alternatively mock treated as control (ÀIM) (Supplementary Figure 1) . Cell lysates, cell aliquots, and cDNA of each clone were preserved monthly during the course of IM-resistance induction for later analysis. Two clones, resistant to 41 mM IM, were analyzed for the role of Akt activation as a putative early mechanism of IM resistance: (i) clone 14 þ IM, which developed a clinically relevant BCR/ABL-kinase point mutation Gln252His ( Figure 1A , a) and (ii) clone 10 þ IM with a BCR/ABL-dependent, unknown mechanism of IM resistance.
In clone 14 þ IM, mutated Gln252His-cDNA traces were first detected at day 80 (d80) (9% mutated signal) and increased to 72% at d110, suggestive of clonal expansion ( Figure 1A, b) . 
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Analysis of cryo-preserved aliquots of clone 14 þ IM derived from days 0, 80, 110, and 140, respectively, revealed that strong IM resistance occurred only after day 110 þ IM, that is, after expansion of Gln252His-mutated cells to 470% ( Figure 1B) . BCR/ABL expression remained unchanged in clone 14 þ IM throughout the experiment (not shown). Hence, IM resistance/ survival of clone 14 before d110 was due to mechanisms other than the Gln252His-point mutation or BCR/ABL overexpression. When compared to d0, survival of cells from d50 þ IM ( Figure  1C , a, b) could be attributed, to a great extent to an activation of the anti-apoptotic PI3K/Akt pathway, because d50 þ IM cells were only killed in the presence of IM after the PI3K inhibitor wortmannin (WM) was added ( Figure 1C, b) . In line with this biological observation, only the co-administration of IM and WM, but neither of the drugs alone, blocked Akt-phosphorylation (p-Akt) and Akt kinase activity, as assessed by means of phosphorylation of the Akt-specific substrate GSK3a/b ( Figure  1C, b) . Notably, clone 14 lost its strong dependence on PI3K for survival in the presence of IM at d180 (with 480% Q252H-positive cells in culture), indicating stage-specific roles for this pathway during manifestation of IM resistance. Clone 10 þ IM developed BCR/ABL-dependent IM resistance around d220 (Figure 2a and b) . BCR/ABL overexpression (Figure 2b ) as well as BCR/ABL-kinase mutation (not shown) was excluded as resistance mechanism. Akt activation again occurred before emergence of strong IM resistance at d220 (Figure 2c) , and contributed to IM resistance: SH-6, a novel selective Akt inhibitor, 39 killed clone 10 only at d180 but not at d220 (Figure 2d ). This illustrated that clone 10 particularly depended on Akt-signaling for survival at d180, but not at d220 (Figure 2a and d) . These findings were validated using Akt1-specific siRNA. Akt1-siRNA equally down-regulated Akt1 at d180 and d220 (Figure 2e, upper panel) , but apoptosis was augmented only at d180 (Figure 2e, lower panel) . Stronger IM resistance at d220 was associated with an increased phosphorylation of p70S6K (p T389 p70S6K) compared with d180 (Figure 2e ), indicating that activated p70S6K contributed to stronger IM resistance at d220.
Compensatory activation of Akt and p70S6K contributes to survival and IM resistance development p70S6K-Western blotting of Akt1-and control-siRNA-treated clone 10-aliquots from d180 and d220. Lower panel: increase in apoptosis by Akt1-specific siRNA compared to control-siRNA as assessed by Annexin-FITC/PI-staining. Four independent experiments were performed. Bars: 7s.d. '*' indicates statistically significant differences.
Akt activation and imatinib resistance A Burchert et al exposed to IM or, alternatively, to IM and Rap. Neither clone 10, nor clone 14 developed a kinase mutation in this experiment (not shown). In analogy to the results above (Figures 1, 2c and e), IM treatment prompted an activation of Akt (clones 10 and 14), or the downstream target of Akt, p T389 p70S6K (clone 10) (Figure 3a) . Notably, mTor-inhibition with Rap prevented Akt activation by IM (Figure 3a ) and retarded IM resistance development (Figure 3b) . Similar results were obtained in two primary cell samples (Figure 3c and d) . IM at 0.5 mM, administered for up to 9 days, activated Akt and p70S6K in IM-naïve CML blasts, but did not increase apoptosis (Figure 3c ). In turn, Rap antagonized IM-induced Akt activation, resulting in apoptosis (Figure 3c ). Cells derived from another CML patient in chronic phase, who lost hematological response due to incompliant IM intake (irregular and reduced IM-doses), displayed high p T389 p70S6K levels and a constitutive phosphorylation of Akt (Figure 3d) . Treatment of these cells with 1 mM IM for 48 h only partially inhibited p T389 p70S6K, but neither affected p-Akt levels, nor apoptosis (Figure 3d ). In contrast, 10 nM Rap for 48 h completely inhibited p-AKT and p T389 p70S6K and caused significant apoptosis (Figure 3d ). Altogether, these data are in line with the concept that IMnaïve BCR/ABL-positive cells employ a compensatory Akt/mTorsignal activation to escape BCR/ABL inhibition through IM.
The mTor-inhibitor RAD001 inhibits IM resistance development in a novel cell-based resistance induction assay
If Akt/mTor signaling is predominantly required for incipient IM resistance, we reasoned that mTor inhibition would block IM resistance development also in a novel recently reported cellbased strategy for induction of inhibitor resistance. 38 In this assay, an alternative mTor inhibitor, RAD001 40 was used. RAD001 (unlike Rap) is being developed in oncology and is clinically well tolerated. 41 RAD001 dose dependently reduced the frequency of IM-resistant colonies by 59 and 94% of the IM control, respectively (Figure 4a ). This strikingly potent efficacy of RAD001 may be explained only to some extend by its growth-inhibitory effects, because low doses of RAD001 only marginally inhibited proliferation of Ba/F3-BCR/ABL cells (Figure 4b ) and did not affect apoptosis in short-term cultivation experiments (Figure 4c ).
Heterogeneous activation of Akt and p70S6K in IM-resistant patients with BCR/ABL-kinase mutation
We reasoned that PI3K-signaling may be particularly important for early IM resistance. Blockage of mTor has been shown to 
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A Burchert et al overcome manifest IM-resistance in vitro and in animal studies, 34, 35 and blocking of an activated Akt-/mTor-signaling has been suggested as a means to overcome clinical IM resistance. 34, 35 Here, we analyzed the activation status of Akt and mTor in CML patients (n ¼ 17) with clinically overt IM resistance through kinase mutations (n ¼ 15). Each of the 17 tested patient samples was derived during clinical IM resistance, with a 100% Ph þ -status as mirrored by the high BCR/ABL-ABL mRNA ratios ranging between 40 and 100% ( Figure 5A ). All patients were on IM (for indicated times) at the time of sample acquisition ( Figure 5A ). In spite of the presence of a mutated BCR/ABL kinase, only a minority of the patients displayed an activation of the downstream targets of BCR/ABL, Akt (n ¼ 7), and p70S6K (n ¼ 8), which is downstream of Akt ( Figure 5A ). Even patients harboring the same mutation, such as the Tyr253His-mutation in patients #1, #3, #4, #5, and #6, showed inconsistent Akt, p-Akt, and p T389 p70S6K-expression levels ( Figure 5A ). There was also no clear correlation between Akt expression, Akt phosphorylation, and p70S6K-activation, indicating no linear activation mode of this pathway during manifest IM resistance ( Figure 5A ). Hence, Akt/mTor activation occurs independently from BCR/ABL and may therefore variably contribute to overt IM resistance in vivo. We therefore tested two successive IM-resistant patients with ALL and found that only the patient with strong p T389 p70S6K-expression and high levels of p-Akt ( Figure 5B, a) responded to Rap in vitro, whereas the second patient with low levels of p T389 p70S6K and p-Akt did not respond to Rap treatment in vitro ( Figure 5B ). Susceptibility to Rap in patient #18 was associated with a decrease of p-Akt and p T389 p70S6K ( Figure 5B ). This suggests that the variable degree of Akt/mTor activation in IM-resistant patients with CML or ALL Akt activation may predict responsiveness to mTorinhibitor treatment.
Discussion
We here demonstrated three principal findings. First, it is shown that Akt/mTor-signaling is activated in response to IM-exposure of IM-naïve cells. Secondly, IM-induced Akt activation is critically involved in mediating early IM-resistance and inhibition of mTor prevents IM-induced Akt activation and IM resistance development. Finally, a heterogeneous Akt-signaling-cascade activation is demonstrated during manifest IM resistance independently from BCR/ABL-kinase mutations. This may have implications for the responsiveness to mTor-inhibitor treatment. Our findings suggest distinct roles for Akt-signaling activation during incipient and manifest IM resistance.
BCR/ABL-positive minimal residual disease (MRD) can be detected by PCR in most of the IM-treated CML-and Ph þ -ALL patients in complete cytogenetic remission, 7, [42] [43] [44] providing evidence for persistence of BCR/ABL-positive cells in the presence of IM, which is mechanistically poorly understood, and cannot well be explained with BCR/ABL-kinase mutations. It has been suggested that stem cells may escape IM-mediated apoptosis due to the inability of IM to attack quiescent stem cells 42 or by IM-drug efflux mechanisms. 45, 46 In an attempt to address the question how BCR/ABL-positive cells can survive IM treatment in the absence of kinase mutations, we used clonal populations of BCR/ABL-positive cells to induce IM resistance. During IM-resistance induction, cell aliquots were prospectively collected at various time points allowing later genetic and biological analysis. This methodology led to the hypothesis that activation of PI3K/Akt-signaling mediates survival under IM-challenge and precedes the emergence of strong IM resistance ( Figures 1D and 2) . The validity and significance of this working hypothesis was confirmed by several means. First, IM-induced Akt activation was recapitulated using the same original IM-naïve starting populations of clones 10 and 14 ( Figure 3a) . Secondly, IM elicited a time dependent Akt-/mTor-activation also in primary BCR/ABLpositive cells in vitro (Figure 3c ) and in vivo (Figure 3d ). In fact, according to the data shown in Figure 3 , Akt-pathway activation can be detected in IM-sensitive patients in vivo in the presence of IM and provides a survival signal for BCR/ABLpositive cells exposed to IM.
Akt-signal activation in response to BCR/ABL inhibition by IM may appear illogical, because BCR/ABL is upstream of Akt. On the other hand, the findings are mechanistically reminiscent to recently published data, describing an activation of the Ras/ MAPK-signaling pathway in presence of IM. [16] [17] [18] [19] Chu et al 19 additionally reported in their study that the Akt-activity was unexpectedly not inhibited by IM treatment of primary CMLcells. In view of our results, their observation could also be interpreted as a compensatory Akt activation after BCR/ABL inhibition, resulting in a maintained Akt-activation status. Thus, evidence is accumulating that incipient IM resistance may result from recruitment of signal activity downstream of BCR/ABL, which confers survival after inhibition of BCR/ABL. Both Akt and p70S6K can receive signal input through other kinases and proteins such as PDK-1, 26, 27 Src, the insulin receptor substrate (IRS)-1, and Ras. 47 However, members of the Akt-signaling cascade are apparently also variably and autonomously activated in IM-resistant patients with BCR/ABL kinase mutations ( Figure 5A ). It is thus tempting to speculate, that a hyperactivation of Akt or mTor in individual patients contributes independently from BCR/ABL's activation status to the biology of IM resistance. For example, activation of PI3K/mTor signaling increased the formation of reactive oxygen species thereby contributing to BCR/ABL transformation, but mTor inhibition antagonized this. 48 Thus, selective mTor-pathway activation may translate into a differential effectiveness of mTor inhibitors in overcoming IM resistance. This idea is suggested from studies with mTor inhibitors in AML 49 and solid cancers, 50 but is also shown in two patients with IM-resistant, Ph þ -ALL in this study ( Figure 5B ). This may be relevant, because even though it is established that inhibitors of the PI3K/Akt-signaling pathway, including Rap, or a novel PDK-inhibitor 51 synergize with IM to mediate apoptosis of BCR/ABL-positive cells, 21, 34, 35, 51 determinants for responsiveness to PI3K/Akt/mTor inhibitors of IMresistant disease in vivo are unknown. A third line of support that the PI3K/Akt-signaling is particularly important to mediate survival in response to IM-challenge came from mTor-inhibitor studies, where Rap and RAD001 significantly retarded or potently prevented de novo IM resistance development in vitro (Figures 3b and 4) . These positive results are not unexpected. 21, 34, 35, 51 However, our work extends previous findings by showing that the synergism between Rap/RAD001 and IM in preventing IM resistance (Figure 4 ) may be particularly due to the prevention of an IM-induced activation of Akt-signaling by mTor inhibitors (Figure 3) . IM-induced PI3K/Akt/mTor activation could contribute to a persistence of BCR/ABL-positive cells in CML patients and thus facilitate the evolution of strong, BCR/ ABL-dependent IM resistance. Notably, it has been shown that the PI3K/Akt pathway activation is also important in mediating resistance to another kinase inhibitor, gefitinib, in lung cancer. 22 The use of mTor inhibitors in combination with IM thus appears to be particularly suitable before strong, BCR/ABL-dependent resistance occurs. We have recently inaugurated an imatinib/ RAD001 combination trial in CML patients with suboptimal IM response to specifically address this question. 
